Home › Funds › DAFNA Capital Management LLC › NGNE
DAFNA Capital Management LLC position in NGNE
NEUROGENE INC COM · Health Care
DAFNA Capital Management LLC reported holding 89,032 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$2.8M, representing 0.53% of its reported portfolio and ranking #37 among its reported holdings. DAFNA Capital Management LLC has disclosed NGNE holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DAFNA Capital Management LLC's NGNE position evolved
DAFNA Capital Management LLC first disclosed a stake in NGNE in Q2 2024 at 11,000 shares (US$400K). The position peaked in Q2 2026 at 89,032 shares, worth US$2.8M. Across 9 filings, DAFNA Capital Management LLC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 89,032 shares valued at US$2.8M — an increase of 32,397 shares quarter over quarter.. Notable position changes include a 562% increase in Q4 2024 (shares fell 49% over the following quarter), a 102% increase in Q1 2026 (shares rose 56% over the following quarter), a 57% increase in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 11.00K | $400.29K | New |
| Q3 2024 | 7.78K | $326.24K | Reduce |
| Q4 2024 | 51.50K | $1.18M | Add |
| Q1 2025 | 51.50K | $603.07K | Hold |
| Q2 2025 | 51.10K | $763.88K | Reduce |
| Q3 2025 | 30.38K | $526.40K | Reduce |
| Q4 2025 | 27.97K | $576.26K | Reduce |
| Q1 2026 | 56.63K | $1.14M | Add |
| Q2 2026 | 89.03K | $2.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), Redmile Group, LLC (US$44.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.72M sh · $54.00M · Q2 2026
- Casdin Capital 1.55M sh · $48.60M · Q2 2026
- Redmile Group, LLC 1.41M sh · $44.41M · Q2 2026
- RTW INVESTMENTS, LP 1.36M sh · $42.85M · Q2 2026
- EcoR1 Capital, LLC 1.27M sh · $39.98M · Q2 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $31.19M · Q2 2026
- Trails Edge Capital Partners, LP 714.88K sh · $22.48M · Q2 2026
- GREAT POINT PARTNERS LLC 352.18K sh · $11.08M · Q2 2026
More on DAFNA Capital Management LLC
FAQ
How long has DAFNA Capital Management LLC held NGNE?
DAFNA Capital Management LLC has disclosed NGNE holdings in 9 of the last 9 reported quarters, going back to Q2 2024.
What is DAFNA Capital Management LLC's current position in NGNE?
As of Q2 2026, DAFNA Capital Management LLC holds 89.03K shares of NGNE (NEUROGENE INC COM), valued at $2.80M, representing 0.53% of its reported portfolio and ranking #37.
Has DAFNA Capital Management LLC been buying or selling NGNE?
In the latest 13F filing (Q2 2026), DAFNA Capital Management LLC increased its position in NGNE. The position peaked in Q2 2026 at 89.03K shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.